IFNLR1 Antibody (YA8842)

Cat. No.: HY-P89158: Ficha de datos User Guide for Antibodies
FAQs
Technical Support

IFNLR1 Antibody (YA8842) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IFNLR1.

Para uso exclusivo en investigación. No vendemos a pacientes.

Tamaño	Stock	Cantidad
20 μL	Obtener un presupuesto 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
50 μL	Obtener un presupuesto 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
100 μL	Obtener un presupuesto 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
250 μL	Obtener un presupuesto

Synthetic products have potential research and development risk.

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Descripciòn

Descripciòn

IFNLR1 Antibody (YA8842) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IFNLR1.

Host

Mouse

Clonality

Monoclonal

Species Reactivity

Human

SwissProt ID

Q8IU57

Immunogen

Human recombinant protein fragment corresponding to amino acids 21-228 of human IFNLR1 produced in E.coli.

Application &
Dilution Ratio

Application	Dilution Ratio
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:500-800

Sensitivity	Endogenous	Pureza	Affinity purified
Conjugation	Non-conjugated	Modification	Unmodified
Isotype	IgG1

Appearance

Liquid

Formulation

Spplied in PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Envío

Shipping with blue ice.

Background

Function：The IFNLR1/IL10RB dimer is a receptor for the cytokine ligands IFNL2 and IFNL3 and mediates their antiviral activity. The ligand/receptor complex stimulate the activation of the JAK/STAT signaling pathway leading to the expression of IFN-stimulated genes (ISG), which contribute to the antiviral state. Determines the cell type specificity of the lambda interferon action. Shows a more restricted pattern of expression in the epithelial tissues thereby limiting responses to lambda interferons primarily to epithelial cells of the respiratory, gastrointestinal, and reproductive tracts. Seems not to be essential for early virus-activated host defense in vaginal infection, but plays an important role in Toll-like receptor (TLR)-induced antiviral defense. Plays a significant role in the antiviral immune defense in the intestinal epithelium

Subcellular Localization：Membrane

Expression：
Tissue_Specificity: Widely expressed

Isoforms & Post-Translational Modification：Q8IU57 has four isomers: Q8IU57-1: 57653 Da (predicted); Q8IU57-2: 54415 Da (predicted); Q8IU57-3: 23689 Da (predicted); Q8IU57-4: 27536 Da (predicted).
Ubiquitinated by FBXO45-containing E3 ligase leading to proteasomal degradation

Subunit：Heterodimer with IL10RB

Synonyms

CRF2/12; IFNLR; IL-28R1; IL28RA; LICR2

Documentación

User Guide for Antibodies (1077 KB)